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Microsomal epoxide hydrolase is not a
2-arachidonyl glycerol hydrolase
Michael Arand, Anne Marowsky
Institute of Pharmacology and Toxicology, University of Zurich (CH);
The endocannabinoid 2-arachidonyl glycerol (2-AG) is substantially hydrolysed by at least two
enzymes, fatty acid amide hydrolase (FAAH) and monoarachidonyl glycerol lipase (MAGL),
which thereby terminate its biological activity. In a recent report it has been claimed that
microsomal epoxide hydrolase (mEH), hitherto known as a xenobiotic detoxifying enzyme,
also rapidly catalyses the breakdown of 2-AG. However, the catalytic site architecture of
mEH argues against an esterase activity. We therefore analyzed the capacity of recombinant
puriﬁed human, mouse and rat mEH to hydrolyze 2-AG. In contrast to the previous ﬁnding,
we ﬁnd only marginal 2-AG esterase activity ( ≤ 50 nmol/mg protein/min) associated with
the puriﬁed enzymes that was resistant to inhibition by the potent mechanism-based mEH
inhibitor 1,1,1-trichloropropene 2,3-oxide (TCPO). Likewise, 2-AG hydrolysis in mouse liver
microsomes was resistant to TCPO inhibition while being eﬃciently blocked by methyl
arachidonyl ﬂuorophosphonate (MAFP). MAFP, on the other hand, failed to inhibit epoxide
hydrolase activity of both, puriﬁed mEH and mouse liver microsomes. We therefore conclude
that mEH lacks any appreciable 2-AG hydrolase activity.
Objective
We therefore set out to re-assess the potential activity of mEH as a 2-AG hydrolase by
directly testing this activity with puriﬁed mEH.
Introduction
In a recent publication, Nithipatikom and colleagues (Nithipatikom 2014[1]) claimed
that the xenobiotic-metabolising enzyme microsomal epoxide hydrolase (mEH) (Oesch
1973[2]) eﬃciently hydrolyses the endocannabinoid 2-arachidonyl glycerol (2-AG) (Me-
choulam 1995[3]). Endocannabinoid signaling is important for a variety of physiological
processes such as pain sensation (Hohmann 2005[4]), cognition and emotion (Crowe
2014[5]) and appetite regulation (Di Marzo_2001[6]). Thus the capability of mEH to con-
trol 2-AG levels would have substantial implications, also because mEH is almost ubiqui-
tously expressed throughout the human body (Coller 2001[7]).
The study by (Nithipatikom 2014[1]) was inspired by the fact that mEH belongs to the
structural superfamily of α/β hydrolase fold enzymes (Zou 2000[8]) and therefore shares
structural similarity to a wide range of esterases and lipases (Lenfant 2013[9]). Two of
these, ABHD6 and ABHD12, have recently been shown to posses 2-AG hydrolase activ-
ity (Blankman 2007[10]).
In their experiments, the authors used microsomes of cell lines (over)expressing mEH.
Microsomes are membrane preparations obtained by diﬀerential centrifugation of cell or
tissue homogenates and contain essentially all the membrane-associated proteins that are
not conﬁned to large organelles such as nuclei and mitochondria. Therefore, the contri-
bution of mEH to the total protein content of these microsomes probably does not exceed
1%. Unfortunately, the authors do not give quantitative measures for this, but the fact that
they use 30 µg microsomal protein for their Western blot analyses is in agreement with
the above estimate. In their turnover experiments, the authors observed 2-AG hydrolysis
in microsomes that, after subtraction of the signiﬁcant background reaction observed in
non-transfected material, correlated with the degree of mEH expression and was respon-
sive to siRNAmediated mEH down regulation and inhibition by small molecules, the most
potent of these being methyl arachidonyl ﬂuorophosphonate (MAFP). From their results,
they conclude that mEH is a novel 2-AG hydrolase.
Some facts cast doubt on the interpretation of the study: 1) Although mEH is indeed a
member of the α/β hydrolase fold enzyme superfamily, it belongs to a sub-class that diﬀers
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in the most important component of its catalytic machinery from esterases and lipases:
While the active site catalytic nucleophile of lipases/esterases is a serine that forms a covalent intermediate with the
acid component of its ester substrates (Sussman 1991[11]), epoxide hydrolases carry an aspartic acid at this position,
forming an ester intermediate with the alcoholic component of its substrates (Lacourciere 1993[12]) (Fig. 1A; Fig. S1 for
a more detailed explanation).2) The control membrane preparations used in the study posses already a high background
activity for 2-AG hydrolysis that is not attributable to mEH, FAAH or MAGL, and the increase in activity, where it can
be taken from the authors presentation, is only a 2 - 3-fold gain, 3) the strongest inhibitor identiﬁed in the study, MAFP,
is known as a powerful inhibitor of PLA2-type lipases (Lio 1996[13]), yet no potency to inhibit mEH has so far been
demonstrated, and ﬁnally 4) neither 2-AG hydrolytic activity nor sensitivity to MAFP inhibition of puriﬁed mEH have
been tested by the author, which would be a deﬁnitive proof for their claim.
(A) The separate types of α/β hydrolase fold enzymes use diﬀerent catalytic residues to hydrolyse diﬀerent types of sub-
strates: while epoxide hydrolases cleave the ether bond in epoxides with an aspartic acid side chain, esterases hydrolyse
esters using a serine side chain (for further details see Fig. S1). Epoxide hydrolase activity of puriﬁed human mEH
(B) and of mouse liver microsomes (D) is sensitive to TCPO inhibition and resistant to MAFP treatment. In contrast,
2-AG hydrolase activity of puriﬁed human mEH (C) and of mouse liver microsomes (E) is resistant to TCPO treatment,
while this activity in liver microsomes is strongly inhibited by MAFP. The column heights give the mean of 3 separate
measurements. Error bars indicate the standard deviation. *** p < 0.001
NB: MAFP sensitivity of 2-AG hydrolase activity associated with the human mEH puriﬁed from bacteria was not tested
because of the lack of relevance: the bacterial enzyme obviously contributing this activity (see our collective results)
may or may not be inhibited by the compound. Either result would not have any impact on our conclusions.
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Results & Discussion
Recombinant expression and His-tag-based metal chelate chromatography puriﬁcation yielded puriﬁed mouse, rat and
human mEH protein that displayed turnover rates with the prototypic substrate 11,12-epoxyeicosatrienoic acid (11,12-
EET) of 0.1, 0.3 and 0.65 µmol per mg protein per minute, respectively. On SDS polyacrylamide gel electrophoresis
and subsequent Coomassie staining the recombinant proteins displayed the expected dominant signal at 52 kDa (Fig.
S2A), with some minor impurities amounting to 14, 18 and 27% for the rat, mouse and human enzyme, respectively, as
determined by densitometric quantiﬁcation.
2-AG turnover with puriﬁed rat, mouse and human mEH revealed relatively poor, apparently TCPO-resistant enzymatic
activity (Fig. S2B-G) that roughly correlated with the degree of impurity of the enzyme preparation. The most active
preparation was that of human mEH with an estimated turnover rate of 50 nmol arachidonic acid formed per milligram
protein per minute. Because the activity reported by (Nithipatikom 2014[1]) for human mEH was several orders of
magnitudes higher (see last paragraph of this section for a comparison), these results already demonstrate that mEH
does not possess substantial 2-AG hydrolase activity. However, to clarify whether the measurable 2-AG hydrolase
activity in our recombinant puriﬁed enzymes might be attributed to any impurities of the preparation rather than to
mEH itself, we reﬁned the analysis of enzymatic turnover in the presence and absence of 1,1,1-trichloropropene 2,3-
oxide (TCPO), a potent mEH inhibitor. This compound acts as a suicide substrate, characterised by an extremely slow
hydrolysis rate of the covalent intermediate formed in the ﬁrst step. Therefore, any activity of the enzyme requiring
the catalytic nucleophile is eﬃciently blocked by a suﬃcient TCPO concentration. In presence of 1 mM TCPO, 99% of
the human mEH enzymatic activity were blocked using 4 uM 11,12-EET as substrate (Fig. 1B; the Km for human mEH
with 11,12-EET is reported to be 0.4 µM (Decker 2012[14])). By contrast, 2-AG hydrolysis by human mEH remained
essentially unchanged with 100 µM 2-AG (Fig. 1C; the Km with 2-AG is 40 µM according to (Nithipatikom 2014[1])).
This shows that 2-AG hydrolytic activity is not associated with the mEH protein itself, but is most probably due to minor
impurities of bacterial esterases in our enzyme preparation. In addition, we tested MAFP for its capability to block mEH
hydrolase activity. With an IC50 of 7.9 nM this compoundwas identiﬁed as themost potent inhibitor by (Nithipatikom
2014[1]) to block what they proposed to be mEH-mediated 2-AG hydrolysis. However, 11,12-EET hydrolysis by puriﬁed
human mEH remained unaﬀected in the presence of 10 µM MAFP (Fig. 1B).
To test whether the native membrane environment in the endoplasmic reticulum provides essential components for
any mEH-mediated 2-AG hydrolytic activity which might explain the lack of the respective enzymatic activity with the
puriﬁed enzyme, we next analysed 2-AG and 11,12-EET hydrolysis in microsomes prepared from the livers of sEH -/-
mice, lacking the mEH sister enzyme soluble epoxide hydrolase (sEH), the presence of which might otherwise interfere
with the eﬃcacy of TCPO to inhibit 11,12-EET hydrolysis. In the absence of any inhibitor, the microsomes showed the
expected hydrolytic activities with 11,12-EET (0.66 nmol/mg/min; Fig 1D) and 2-AG (950 nmol/mg/min; Fig 1E). Again,
EET hydrolysis was highly sensitive to TCPO inhibition and resistant to MAFP treatment (Fig. 1D), while the opposite
eﬀect was observed with 2-AG hydrolysis (Fig 1E).
The 2-AG hydrolase activity reported by (Nithipatikom 2014[1]) is very high. From Fig. 4 of their manuscript, an
enzymatic activity of around 300 nmol 2-AG being hydrolyzed per minute and milligram microsomal protein can be
deduced. Given the above estimate that at best 1% of the microsomal enzyme can be attributed to mEH, this would
imply that mEH has a speciﬁc 2-AG hydrolase activity of ≥ 30 µmol per milligram per minute. We do not ﬁnd activity
with puriﬁed mEH from either rat, mouse or human in excess of 50 nmol per milligram per minute. On top, the inhibitor
sensitivity of both, the 2-AG hydrolysis by puriﬁed mEH enzyme as well as of mouse liver microsomes, is incompatible
with its origin from mEH, but suggests that even this minor activity in our preparations originates from bacterial en-
zymes that have not completely separated from the mammalian proteins during puriﬁcation.
Conclusions
Our results clearly demonstrate that mEH lacks any appreciable 2-AG hydrolase activity. With respect to the obser-
vations made by (Nithipatikom 2014[1]), we suggest as an alternative explanation that mEH might activate a so far
uncharacterized MAFP-sensitive 2-AG hydrolase.
Conjectures
The next obvious step is to identify the 2-AG hydrolase that is apparently activated by mEH, as well as the mechanism
by which this activation takes place. According to the report by Nithipatikom et al., this hydrolase can neither be FAAH
nor MAGL. In our view, the potential candidates are ABHD6, ABHD12, CES1 and CES2, due to their reported signiﬁcant
capacity to hydrolyze 2-AG (Blankman 2007[10]) (Xie 2010[15]).
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Figure legends 
 
Fig. S1 Structure and enzymatic mechanism of human mEH in comparison to 
the enzymatic mechanism of serine hydrolases, example ABHD12 
A. Stereoview of a 3D model of human epoxide hydrolase showing the active site residues. 
The model is based on the structure of the related juvenile hormone epoxide hydrolase from 
Bombyx mori (Zhou et al. Proteins (2014) 82, 3224-3229). The respective PDB file is also 
provided as Supplementary Material (hmEH model.pdb) for further inspection. 
B. The two step mechanism of enzymatic epoxide hydrolysis by mEH. In a first step of the 
catalysis, the catalytic nucleophile Asp226 attacks an electron-deficient carbon of the oxirane 
ring to form an ester intermediate. This intermediate is subsequently hydrolyzed by means of 
the water-activating His431-Glu404 pair, the so-called charge relay system. The two tyrosines 
Tyr290 and Tyr 374 are important hydrogen bond donors that activate the substrate molecule 
and keep it in favourable position for the attack by Asp226. Note that the acid component of 
the ester intermediate is provided by the enzyme. 
C. The two step mechanism of enzymatic ester hydrolysis typical for serine hydrolases. The 
first step of enzymatic hydrolysis is a transesterification of the acidic component of the 
substrate molecule from its alcoholic part to the catalytic serine of the enzyme, Ser246 in 
ABHD12 (Navia-Paldanius et al. J. Lipid Res. (2012) 53, 2413-2424). Subsequent hydrolysis 
takes place analogous the the above mechanism with a similar charge relay system, His372-
Asp333 in ABHD12. This time, the acid component of the ester intermediate originates from 
the substrate. The possibility to swap substrates between these two types of related yet 
substantially different mechanisms is not obvious. 
 
Fig. S2 2-AG hydrolysis by purified mammalian mEHs in the absence and 
presence of the mEH-specific inhibitor TCPO 
A. Visualization of purified rat (lanes 1 + 2), mouse (lanes 2 + 3) and human (lanes 5 + 6) mEH 
after His-tag purification. 4 µg of protein were loaded on each lane and the SDS-polyacryl-
amide gel was stained with Coomassie brilliant blue after electrophoretic separation of 
proteins. Marker proteins (lane M) were used to monitor the apparent molecular weight of the 
sample proteins. Of the two separate purification batches of each protein, the one labelled by 
an arrow was used for the subsequent  turnover experiments. 
B. – G. Ion chromatograms of 2-AG turnover with rat (B, C), mouse (D, E) and human (F, G) 
mEH in the absence (B, D, F) and presence (C, E, G) of TCPO. The red arrow indicates the 
small peaks obtained for arachidonic acid liberated during enzymatic hydrolysis. Procedure 2 
was used for chromatographic separation. Under these conditions, the substrate 2-AG is not 
detected. 
 
Fig. S3 Refined analysis of 2-AG and 11,12-EET turnover by purified human 
mEH 
A. – D. Ion chromatograms of 2-AG hydrolysis by purified human mEH (lane 5 in Fig. S2A). A 
and B show the signal for arachidonic acid (1 µM in assay buffer) and 2-AG (100 µM in assay 
buffer), respectively. C and D depicts the signal after turnover in the absence (C) and 
presence (D) of the mEH inhibitor TCPO. C2 and D2 are magnifications to better show the 
arachidonic acid signal intensity that is almost invisible at normal scale (C1 and D1). 
Chromatographic separation was performed using procedure 3. The red arrows indicate the 
position of arachidfonic acid. 
E. – G.  Ion chromatograms of 11,12-EET hydrolysis by the same enzyme preparation. E 
shows the substrate under starting conditions (4 µM) while F and G present the signal after 
substrate turnover in the absence (F) and presence (G) of TCPO. The strong signal reduction 
for the product 11,12-DHET in the presence of TCPO is obvious. Note, that also the scale has 
changed to higher sensitivity, due to the fact that the less sensitively detected substrate is now 
limiting the scale (note that, with the exception of 3C2 and 3D2, all chromatograms are 
presented as screen shots without adjustmet of the scale, for the sake of authenticity; only 
external rulers have been added to facilitate the reading of the scales). Chromatographic 
separation was performed using procedure 1. The red arrow indicates the position of 11,12-
DHET. 
 
Fig. S4 2-AG and 11,12-EET turnover by mouse liver microsomes 
A. – C. Ion chromatograms of 2-AG hydrolysis by mouse liver microsomes without inhibitor (A), 
as well as in the presence of TCPO (B) or MAFP (C). The red arrow indicates the position of 
the product arachidonic acid. Chromatographic separation was performed using procedure 2. 
D. – F.  Ion chromatograms of 11,12-EET hydrolysis by mouse liver microsomes without 
inhibitor (D), as well as in the presence of TCPO (E) or MAFP (F). The red arrow indicates the 
position of the product 11,12-DHET. Chromatographic separation was performed using 
procedure 2. 
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